| The Antibody Response Against p53 in Cancer Patients | p. 1 |
| Enhanced Production of Wild-Type p53 Inhibits Growth and Differentiation of Normal Foreskin Epithelial Cells but Not Cell Lines Containing Human Papillomavirus DNA | p. 9 |
| Detection of Human Papillomavirus, Epstein Barr Virus and Elevated or Mutant p53 Expression in Squamous Cell Carcinoma of the Head and Neck | p. 15 |
| Elevated Levels of the p53 Tumour Suppressor Gene in the Basal Layer of Recurrent Laryngeal Papillomas | p. 21 |
| Expression of the E6 and E7 Genes of Human Papillomaviruses in Tumours of Different Dignity | p. 25 |
| Detection of HPV-16 E2 Protein in Cervical Keratinocytes | p. 33 |
| Evaluation of the Hybrid Capture Assay for Determination of Human Papilloma Virus | p. 39 |
| Utilization of a PCR-based, Multiple Restriction Endonuclease Digest Technique for Enhanced Detection and Typing of HPV from Clinical Samples | p. 45 |
| A Gene Cassette for High Level Expression of the LI Capsid Protein of HPV-16 in Heterologous Cells | p. 51 |
| Genotyping of Human Papillomavirus (HPV) by Single-Strand Conformational Polymorphism (SSCP) | p. 55 |
| Human Papillomavirus Infection in Women with Cervical Cancer but without Cytological Abnormalities in the Preceding Years | p. 59 |
| HPV Infection and Carcinomas of the Larynx | p. 63 |
| Perinatal Transmission and Persistence of the Cancer Associated Human Papillomaviruses | p. 71 |
| HPV-DNA on Colpocytological Smears from HIV Positive Females | p. 75 |
| Humoral Immune Response to Genital Human Papillomavirus Infections | p. 81 |
| HPV 16 Antibodies in Cervical Cancer Patients and Healthy Control Women | p. 85 |
| Prevalence of Antibodies Against Defined HPV Epitopes Among Incident Cases of Cervical Neoplasia: Current Status and Concepts | p. 91 |
| Serological Response to HPV 16 Infection | p. 103 |
| Detection of Antibodies to L1, L2, and E4 Gene Products of Human Papillomavirus Types 6, 11, and 16 among HPV Infected Patients and Controls | p. 109 |
| IgG Antibodies to Human Papillomavirus Type 16 and Serum Retinol May Jointly Protect against Cervical Neoplasia | p. 113 |
| Prognostic Significance of Antibodies to HPV-16 E7/E4 Proteins and Fragments of Cytokeratin 19 in Invasive Cervical Carcinoma | p. 119 |
| Development of Serological Assays for Detection of Anti-HPV-16 E6 and E7 Antibodies | p. 125 |
| Detection by ELISA Test of Antibodies to Human Papillomavirus (HPV) Type 16 E7 in Patients with Benign or Malignant Papillomas from Skin or Mucosa | p. 133 |
| Seroreactivity to a L2-derived Synthetic Peptide Correlates with the Number of Surgery-Necessitating Recurrences in Patients with Laryngeal papillomatosis | p. 139 |
| Comparison of pV Conformational Epitopes Expressed by L1 Proteins in Mammalian (COS) and Insect (Sf9) Cells | p. 147 |
| Detection of Class-Specific Antibodies to Baculovirus-Derived Human Papillomavirus Type 16 (HPV-16) Capsid Proteins | p. 155 |
| Evolution of Class I HLA antigen Presenting Molecules | p. 161 |
| Major Histocompatibility Complex (MHC) Expression and Antigen Presentation in Cervical Cancer | p. 173 |
| Analysis of MHC Class 1 Expression in HPV 16 Positive Cervical Carcinomas, in Relation to c-myc Overexpression | p. 181 |
| Immunogenetic Study of Women with HPV Related Cancer of the Uterine Cervix | p. 189 |
| Recurrent Respiratory Papillomatosis (RRP): Enriched HLA DQw3 Phenotype and Decreased Class I MHC Expression | p. 195 |
| HPV 16-Derived Synthetic Peptides with Ability to Upregulate MHC Class I Expression on RMA-S or T2 Cells as Detected by Enzyme Immunoassay | p. 201 |
| Regulation of MHC Class I, Class II and ICAM-1 Expression by Cytokines and Retinoids in HPV-Harboring Keratinocyte Lines | p. 207 |
| Murine Cytotoxic T Cell Responses to Human Papillomavirus E7 Protein | p. 213 |
| Immune Response to Human Papillomavirus Type 16 E6 Oncoprotein | p. 219 |
| Human Cytotoxic T Cell Epitopes in HPV 11: Relationships Between Allele-Specific Motifs. HLA Binding and Stimulation In Vitro | p. 227 |
| An Immunodominant Region in HPV 16.L1 Identified by T Cell Responses in Patients with Cervical Dysplasias | p. 233 |
| Immunological Aspects of Cervical Carcinoma | p. 243 |
| Analysis of Tumour-Infiltrating Lymphocytes in Cervical Carcinoma | p. 249 |
| Lymphocyte-Mediated Natural Cytotoxicity to HPV 16 Infected Cervical Keratinocytes | p. 255 |
| Skin Test Reactivity to Papilloma Cells is Long Lasting in Domestic Rabbits after Regression of Cottontail Rabbit Papillomavirus Induced Papillomas | p. 259 |
| Modulation of the DTH Response to HPV 16 E7 | p. 267 |
| Fine Characterization of the HPV16 E7 49-57 Tumor Protective Cytotoxic T Cell Epitope "RAHYNIVTF" | p. 275 |
| Vaccination of Cattle With L2 Protein Prevents BPV-4 Infection | p. 283 |
| Immune Responses to HPV 16 E7 | p. 291 |
| Use of Double aro Salmonella Mutants to Stably Express HPV16 E7 Protein Epitopes Carried by HBV Core Antigen | p. 299 |
| An Experimental Tetracycline and Vitamin A Therapy of HPV Infections of the Lower Female Genital Tract | p. 305 |
| Retinoids and IFN-[alpha] Synergistically Decrease Tumor Cell-Induced Angiogenesis and Stimulate Lymphocyte Induced Angiogenesis | p. 309 |
| Release of Soluble Tumor Necrosis Factor-[alpha] (TNF-[alpha]) Receptor by HPV-Associated Neoplastic Cells | p. 315 |
| Contributors Index | p. 321 |
| Subject Index | p. 323 |
| Table of Contents provided by Blackwell. All Rights Reserved. |
